- Evotec and X-Chem have entered a collaboration to enhance early-stage drug discovery using X-Chem’s DNA-encoded library (DEL) technology.
- The partnership will integrate X-Chem’s DELflex and HITMiner platforms with Evotec’s screening capabilities to identify potential drug targets.
Evotec SE has announced a new collaboration with X-Chem to advance early-stage drug discovery. The partnership will utilise X-Chem’s DNA-encoded library (DEL) technology to streamline the process of identifying potential drug candidates.
X-Chem provides access to its DEL technology through two platforms: DELflex, a traditional DEL solution, and HITMiner, a machine learning-based solution. These tools allow for the screening of billions of DNA-tagged compounds, improving the efficiency and precision of hit finding.
This collaboration will integrate X-Chem’s DEL technology with Evotec’s existing screening platforms. “We are pleased to collaborate with X-Chem and leverage their leading DEL platform and capabilities,” said Craig Johnstone, Chief Operating Officer of Evotec. “X-Chem’s expertise, combined with their advanced data-mining solutions, provides us with an additional tool to tackle innovative and difficult biological targets.”
Karen Lackey, CEO of X-Chem, commented, “Partnerships to access best-in-class platforms are the way forward to address the complexity in drug discovery. This collaboration highlights our commitment to making DEL screening services more accessible.”
